AZN ($49.19) is trading below its intrinsic value of $202.69, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
AZN is poor value based on its earnings relative to its share price (40.32x), compared to the US market average (19.9x)
Valuation
AZN is poor value based on its earnings relative to its share price (40.32x), compared to the US Drug Manufacturers - General industry average (8.76x)
Valuation
1 of 13
AZN News
Valuation
AZN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
40.32x
Industry
8.76x
Market
19.9x
AZN is poor value based on its earnings relative to its share price (40.32x), compared to the US market average (19.9x)
Valuation
AZN is poor value based on its earnings relative to its share price (40.32x), compared to the US Drug Manufacturers - General industry average (8.76x)
Valuation
AZN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.26x
Industry
5.12x
Market
-0.01x
AZN is good value based on its book value relative to its share price (8.26x), compared to the US market average (-0.01x)
Valuation
AZN is poor value based on its book value relative to its share price (8.26x), compared to the US Drug Manufacturers - General industry average (5.12x)
Valuation
AZN price to earnings growth (PEG)
For valuing profitable companies with growth potential
AZN is good value based on it's Price to Earnings and rate of earnings growth, measured by PEG ratio (0.82x)
Valuation
AZN's financial health
Profit margin
Revenue
$7.4B
Net Income
$1.0B
Profit Margin
13.6%
AZN's Earnings (EBIT) of $5.22B are insufficient to safely cover interest payments on company debt ($20.38B)
Financials
AZN's profit margin has increased (+6.8%) in the last year from (5%) to (11.8%)
Financials
Assets to liabilities
Assets
$66.7B
Liabilities
$51.1B
Debt to equity
1.3
AZN's short-term liabilities ($20.31B) exceed its short-term assets ($19.54B)
Financials
AZN's long-term liabilities ($30.78B) exceed its short-term assets ($19.54B)
Financials
AZN's debt has increased relative to shareholder equity (3.27), over the past 5 years ago (2.25)
Financials
AZN's debt to equity ratio (3.27) is considered high
Financials
Cash flow
Operating
$1.8B
Investing
$138.0M
Financing
-$2.2B
AZN's operating cash flow ($4.80B) is sufficient to service the company's debt ($20.38B)
Financials
Astrazeneca Stock FAQ
What is Astrazeneca's quote symbol?
(NASDAQ: AZN) Astrazeneca trades on the NASDAQ under the ticker symbol AZN. Astrazeneca stock quotes can also be displayed as NASDAQ: AZN.
What is the 52 week high and low for Astrazeneca (NASDAQ: AZN)?
(NASDAQ: AZN) Astrazeneca's 52-week high was $64.94, and its 52-week low was $46.48. It is currently -24.25% from its 52-week high and 5.83% from its 52-week low.
How much is Astrazeneca stock worth today?
(NASDAQ: AZN) Astrazeneca currently has 1,312,000,000 outstanding shares. With Astrazeneca stock trading at $49.19 per share, the total value of Astrazeneca stock (market capitalization) is $129.07B.
Astrazeneca stock was originally listed at a price of $18.00 in Dec 31, 1997. If you had invested in Astrazeneca stock at $18.00, your return over the last 23 years would have been 173.28%, for an annualized return of 4.47%.
How much is Astrazeneca's stock price per share?
(NASDAQ: AZN) Astrazeneca stock price per share is $49.19 today (as of Apr 13, 2021).
What is Astrazeneca's Market Cap?
(NASDAQ: AZN) Astrazeneca's market cap is $129.07B, as of Apr 15, 2021.
Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.
Astrazeneca's market cap is calculated by multiplying AZN's current stock price of $49.19 by AZN's total outstanding shares of 1,312,000,000.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.